Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have emerged as key agents in the management of T2DM, primarily by inhibiting the SGLT-2 in the kidneys, leading to enhanced glucose excretion and improved glycemic control. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.